Ivacaftor Solvate Crystallization for Purity and Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for new crystalline forms and processes to prepare crystalline forms of ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, to address polymorphism issues affecting solubility, stability, and efficacy in pharmaceutical formulations.

Innovation Solution

The development of crystalline ivacaftor.n-butanol and methanol solvates through specific processes involving treatment with n-butanol or methanol, followed by heating and cooling, to isolate and dry the solvates, resulting in amorphous ivacaftor free from genotoxic impurities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If column chromatography and HPLC purification processes are used to prepare ivacaftor, then purity is improved, but device complexity and manufacturing cost increase

Engineering Contradiction:

ImprovepurityVSAvoidprocess complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent extracts and eliminates the need for complex chromatography purification steps by designing a synthesis route that inherently produces cleaner intermediates and final product, removing unnecessary purification equipment and operations while maintaining high purity standards

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes key synthesis parameters including solvent selection, reaction temperature, and stoichiometry to optimize the reaction pathway, resulting in improved purity without requiring additional complex purification steps, thereby simplifying the overall manufacturing process

Inventive Principle:

Principle #35Parameter changes

2Reliability

If multiple polymorphic forms are investigated to ensure solubility and stability, then reliability is improved, but time and resource consumption increase

Engineering Contradiction:

Improvesolubility and stability predictabilityVSAvoidinvestigation time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary polymorph screening during the early development stages using standardized protocols, identifying the most stable and soluble crystal forms before scale-up, which prevents time-consuming re-investigation during later manufacturing phases

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent systematically investigates phase transitions between different crystalline forms of ivacaftor to identify the most stable polymorph, allowing selection of optimal crystal forms for formulation development and ensuring predictable solubility and stability characteristics

Inventive Principle:

Principle #36Phase transitions

3Reliability

If crystalline solvates are prepared through heating and cooling processes, then solubility is improved, but energy consumption increases

Engineering Contradiction:

ImprovesolubilityVSAvoidenergy consumption

Core Design Contradiction:

ReliabilityVSUse of energy by moving object

Solution Approach 1:

The patent utilizes controlled phase transitions of solvates during heating and cooling cycles to enhance solubility characteristics, leveraging thermodynamic principles to achieve desired dissolution properties while optimizing energy input parameters

Inventive Principle:

Principle #36Phase transitions

Solution Approach 2:

The patent optimizes heating and cooling rate parameters, temperature profiles, and solvent selection to achieve the desired solubility enhancement with minimal energy input, balancing therapeutic benefit with manufacturing efficiency

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The processes yield crystalline and amorphous forms of ivacaftor with defined XRD patterns and thermal properties, enhancing solubility and stability, and ensuring the removal of genotoxic impurities, thereby improving the predictability and efficacy of ivacaftor formulations.

Implementation Method 1

removing the solvent from the solution obtained in (a) by a process comprising (i) filtering the solvent to obtain ivacaftor n-butanol solvate; and (ii) drying the ivacaftor n-butanol solvate at 70-75°c for 20-24 hours to obtain amorphous ivacaftor

Methodology Applied

Scientific EffectPhase transition: Phase Change